

A provider's guide to helping patients afford Amphetamine/Dextroamphetamine XR — covering generic options, discount programs, PAPs, and cost conversation strategies.
For many patients with ADHD, the challenge isn't just getting diagnosed or finding the right dose of Amphetamine/Dextroamphetamine XR — it's affording it month after month. Between the ongoing shortage, insurance coverage gaps, and varying pharmacy prices, medication cost is a significant barrier to adherence.
As a prescriber, you're in a unique position to help. This guide covers what patients are actually paying, the savings programs available, and how to integrate cost conversations into your clinical workflow.
The cost of Amphetamine/Dextroamphetamine XR varies dramatically depending on insurance status, pharmacy, and whether the patient uses a discount card:
The gap between "retail without coupons" and "with a discount card" is enormous — often $150 to $300 per month. Many patients don't know these savings tools exist unless someone tells them.
Several factors drive the price variation:
Unlike many brand medications, Adderall XR no longer has an active manufacturer copay card — the patent has expired and generics are widely available. However, a few relevant programs exist:
Teva, the manufacturer of generic Amphetamine/Dextroamphetamine XR and the original brand Adderall XR, operates a patient assistance program through the Teva Cares Foundation:
For patients who have insurance but face high copays — or who are uninsured — prescription discount cards can dramatically reduce out-of-pocket costs. These are free for patients and accepted at most major pharmacies.
Key points to communicate to patients:
Consider keeping a printed or digital list of discount card options to hand patients after writing a new prescription. A simple handout with "Check SingleCare.com or GoodRx.com before filling your prescription" can save patients hundreds of dollars per year.
Generic Amphetamine/Dextroamphetamine XR is bioequivalent to brand Adderall XR and is the most cost-effective option for most patients. However, there are clinical situations where alternative formulations may better serve your patient's needs and budget:
For a patient-facing comparison, you can direct patients to our guide to Amphetamine/Dextroamphetamine XR alternatives.
Research consistently shows that patients often don't bring up medication cost on their own — they just stop filling prescriptions. Here are strategies to make cost a routine part of your prescribing workflow:
Medfinder for Providers helps you and your staff quickly identify which pharmacies have Amphetamine/Dextroamphetamine XR in stock — so you can send prescriptions to pharmacies that actually have the medication. This saves your patients from the frustrating cycle of pharmacy-hopping during the shortage.
For more strategies on managing the shortage from the prescriber side, see our provider's guide to helping patients find Amphetamine/Dextroamphetamine XR in stock.
Medication cost shouldn't determine whether your patients can manage their ADHD. By knowing the savings options available — from discount cards that cut generic prices to $28/month, to patient assistance programs for the uninsured — you can help remove one of the biggest barriers to treatment adherence.
The most impactful thing you can do is bring up cost before your patient does. A 30-second conversation about discount cards can save them thousands of dollars a year.
Visit medfinder.com/providers to learn how Medfinder can help your practice navigate the Amphetamine/Dextroamphetamine XR shortage and keep your patients on their medication.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.